54
Participants
Start Date
May 15, 2022
Primary Completion Date
January 15, 2024
Study Completion Date
February 15, 2026
penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
"Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows:~Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles.~R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified.~Maintenance treatment:~Combination of two drugs:~* Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months~* lenalidomide: 10 mg, po, for 18 months."
Hematological Department, People's Hospital of Jiangsu Province, Nanjing
ChangZhou First People's Hospital, Changzhou
The First Affiliated Hospital Of Nantong University, Nantong
The First affiliated Hospital of AnHui Medical Universtiy, Hefei
The First Affiliated Hospital with Nanjing Medical University
OTHER